Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5699311 | Clinical Oncology | 2010 | 4 Pages |
Abstract
We present a review of 111 patients who were treated over an initial 3-year period with erlotinib. The median treatment time was 68 days and 59% of patients had stopped treatment within the first 3 months. However, 20 patients were on erlotinib for more than 12 months. Performance status and smoking history were the significant prognostic factors. The overall 3-year survival in patients who had never smoked was 26%.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
J.A.D. Ironside, J.F. English, G.R. Kerr, A. Price, F.A. Little, S.C. Erridge, M.J. Mackean,